Literature DB >> 16682678

Initial pharmacotherapy in a population of veterans with Parkinson disease.

Kari Swarztrauber1, Caroline Koudelka, Matthew A Brodsky.   

Abstract

The authors analyzed patient and prescribing provider characteristics for 530 veterans identified from VA pharmacy records with Parkinson disease (PD) and initial pharmacotherapy. Neurologists prescribed 29% of initial therapy. While a patient being younger and seeing a movement disorder specialist predicted receiving dopamine agonists, only 20% of patients younger than age 65 years received dopamine agonists. Initial pharmacotherapy is strongly influenced by the provider's specialty but mostly initiated by providers without PD expertise.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16682678     DOI: 10.1212/01.wnl.0000210433.49727.40

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  5 in total

Review 1.  Antimuscarinic Anticholinergic Medications in Parkinson Disease: To Prescribe or Deprescribe?

Authors:  Matthew J Barrett; Lana Sargent; Huma Nawaz; Daniel Weintraub; Elvin T Price; Allison W Willis
Journal:  Mov Disord Clin Pract       Date:  2021-10-08

2.  Prescribing pattern of anti-Parkinson drugs in Japan: a trend analysis from 2005 to 2010.

Authors:  Sachiko Nakaoka; Tatsuro Ishizaki; Hisashi Urushihara; Toshihiko Satoh; Shunya Ikeda; Mitsutoshi Yamamoto; Takeo Nakayama
Journal:  PLoS One       Date:  2014-06-06       Impact factor: 3.240

Review 3.  Patterns and Determinants of Prescribing for Parkinson's Disease: A Systematic Literature Review.

Authors:  Khalid Orayj; Emma Lane
Journal:  Parkinsons Dis       Date:  2019-11-03

4.  Prevalence and Correlates of Anti-Parkinson Drug Use in a Nationally Representative Sample.

Authors:  Nabila Dahodwala; Allison W Willis; Pengxiang Li; Jalpa A Doshi
Journal:  Mov Disord Clin Pract       Date:  2016-08-22

5.  Initial medication in patients of newly diagnosed Parkinson's disease in Taiwan.

Authors:  Yi-Jen Guo; Yi-Chu Liao; Ching-Heng Lin; Ming-Hong Chang
Journal:  PLoS One       Date:  2014-09-15       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.